Search

Displaying results 301 - 310 of 2507 in total
  1. Drug

    PG-530742

    go.drugbank.com/drugs/DB05495
    Investigational

    Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis. … PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis.

  2. Drug

    Upinitatug rilsodotin

    go.drugbank.com/drugs/DB19104
    Investigational

    Upinitatug rilsodotin is under investigation in clinical trial NCT05329545 (Upifitamab Rilsodotin Maintenance in Platinum-sensitive Recurrent Ovarian Cancer (UP-NEXT)).

  3. Drug

    IONIS-FGFR4Rx

    go.drugbank.com/drugs/DB16198
    Investigational

    IONIS-FGFR4Rx is under investigation in clinical trial NCT02476019 (A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients).

  4. Drug

    PX-12

    go.drugbank.com/drugs/DB05448
    Investigational

    Initial trials correlated doses of Px-12 with increased patient survival. … PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1α and vascular endothelial growth factor (VEGF) and inhibits

  5. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha. … PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma.

  6. Drug

    Calcium glycerophosphate

    go.drugbank.com/drugs/DB11264
    Approved

    It is suggested that calcium glycerophosphate promotes plaque-pH buffering, elevation of plaque [DB01373] and phosphate levels and direct interaction with dental mineral [A27153].

  7. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    Daridorexant was designed via an intensive drug discovery program to improve the potency and maximize the duration of action while minimizing next-morning residual activity. … treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported, such as next-morning

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Edoxaban

    go.drugbank.com/drugs/DB09075
    ApprovedInvestigational

    is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE

    Categories: P-glycoprotein substrates
  9. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.

  10. Drug

    Fluorodopa (18F)

    go.drugbank.com/drugs/DB13848
    ApprovedInvestigational

    Fluorodopa F 18 is a fluorinated analog of levodopa used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes. Fluorodopa F 18 PET is used adjunctly with other diagnostic investigations...